source
- Kyverna partners with ElevateBio to supply its autologous CAR-T therapy for autoimmune launchesKyverna Therapeutics has signed a five‑year manufacturing agreement with contract development and manufacturing organization ElevateBio. The deal makes ElevateBio the primary supplier of Kyverna's…
- Incyte drops early-stage JAK2 inhibitor to prioritize next-generation pipelineIncyte announced it is terminating development of its early-stage oral JAK2 inhibitor, INCB160058, after a Phase 1 study in myeloproliferative neoplasms. The company said the decision reflects the…